Gene Regulatory Network and Signalling Pathway Rewiring: How Blood Cancer Cells Shift Their Shapes to Evade Drug Treatment
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Kellaway S, Potluri S, Keane P, Blair H, Ames L, Worker A
. Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nat Commun. 2024; 15(1):1359.
PMC: 10867020.
DOI: 10.1038/s41467-024-45691-4.
View
2.
Cruz-Migoni A, Canning P, Quevedo C, Bataille C, Bery N, Miller A
. Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Proc Natl Acad Sci U S A. 2019; 116(7):2545-2550.
PMC: 6377466.
DOI: 10.1073/pnas.1811360116.
View
3.
Bell C, Fennell K, Chan Y, Rambow F, Yeung M, Vassiliadis D
. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nat Commun. 2019; 10(1):2723.
PMC: 6586637.
DOI: 10.1038/s41467-019-10652-9.
View
4.
Assi S, Imperato M, Coleman D, Pickin A, Potluri S, Ptasinska A
. Subtype-specific regulatory network rewiring in acute myeloid leukemia. Nat Genet. 2018; 51(1):151-162.
PMC: 6330064.
DOI: 10.1038/s41588-018-0270-1.
View
5.
Coleman D, Keane P, Chin P, Ames L, Kellaway S, Blair H
. Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. iScience. 2024; 27(4):109576.
PMC: 11024925.
DOI: 10.1016/j.isci.2024.109576.
View